STAAR Surgical - STAA Stock Forecast, Price & News

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Price Performance

Shares of NASDAQ:STAA opened at $104.91 on Tuesday. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $163.08. The business has a 50 day simple moving average of $76.46 and a two-hundred day simple moving average of $71.02. The firm has a market capitalization of $5.02 billion, a PE ratio of 156.58 and a beta of 1.09.

STAAR Surgical (NASDAQ:STAA - Get Rating) last announced its earnings results on Wednesday, August 10th. The medical instruments supplier reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. STAAR Surgical had a return on equity of 13.99% and a net margin of 12.84%. The business had revenue of $81.10 million during the quarter, compared to analyst estimates of $80.12 million. During the same quarter in the previous year, the business earned $0.19 earnings per share. The company's revenue for the quarter was up 30.0% compared to the same quarter last year. Equities research analysts expect that STAAR Surgical will post 0.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

STAA has been the topic of several research reports. Canaccord Genuity Group lifted their target price on STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a report on Tuesday, April 26th. BTIG Research lifted their price target on STAAR Surgical from $98.00 to $103.00 in a research report on Thursday, August 11th. Canaccord Genuity Group lifted their price target on STAAR Surgical from $89.00 to $97.00 in a research report on Thursday, August 11th. Jefferies Financial Group dropped their price target on STAAR Surgical from $165.00 to $125.00 in a research report on Thursday, August 11th. Finally, Needham & Company LLC lifted their price target on STAAR Surgical from $87.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of "Moderate Buy" and a consensus target price of $106.83.

Insider Buying and Selling at STAAR Surgical

In related news, CEO Caren L. Mason sold 35,000 shares of the business's stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $57.49, for a total value of $2,012,150.00. Following the completion of the sale, the chief executive officer now owns 83,645 shares in the company, valued at $4,808,751.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.60% of the company's stock.